{"id":"W2150866539","doi":"10.1634/theoncologist.2014-0028","title":"An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":64,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal","funders":"Eli Lilly and Company","keywords":"Medicine; Ramucirumab; Internal medicine; FOLFOX; Bevacizumab; Oncology; Colorectal cancer; Neutropenia; Progression-free survival; Oxaliplatin; Regimen; Phases of clinical research; Adverse effect; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002242899,0.001919895,0.003598528,0.0006022069,0.0005595866,0.001154838,0.001507169,0.001805228,0.00438519],"category_scores_gemma":[0.001691355,0.0008618286,0.001447352,0.0004393139,0.001620655,0.001292434,0.0003878399,0.00409431,0.001185817],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001261171,"about_ca_system_score_gemma":0.001793681,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000890499,"about_ca_topic_score_gemma":0.001938025,"domain_scores_codex":[0.9992342,0.0003795578,0.00003182315,0.0001521904,0.00007882324,0.0001233496],"domain_scores_gemma":[0.9986332,0.0002440519,0.0002555481,0.0001293304,0.00009835247,0.000639443],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8089221,0.116736,0.001972412,0.0007537361,0.001235276,0.0001850387,0.0001959983,0.001353057,0.01833481,0.0001328743,0.001550249,0.04862859],"study_design_scores_gemma":[0.4975836,0.496375,0.002761963,0.00001907486,0.0002249376,0.0001279113,0.00002268276,0.0009234039,0.001188328,0.00006113184,0.0006928737,0.00001902298],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928213,0.001935955,0.0006939699,0.0002645216,0.0002056126,0.00244664,0.000564828,0.000131552,0.0009357603],"genre_scores_gemma":[0.9894868,0.001309662,0.002410744,0.0005744632,0.0003450487,0.002926795,0.001120793,0.00003504642,0.001790734],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00438519,"threshold_uncertainty_score":0.01466995,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07877267716082854,"score_gpt":0.4312235175892444,"score_spread":0.3524508404284158,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}